NsGene offers a unique combination of novel therapeutic factors and a versatile biodelivery platform that allows the Company to develop, market and sell own biological products as well as making partnerships with the established players in the field of biologics for nervous system disorders. NsGene could be an attractive and valuable investment case for investors with an interest in the growing market of biologics. NsGene and its shareholders are inviting institutional investors to contact NsGene for a discussion of a potential investment in the Company.
Please contact:
President & CEO, Teit E. Johansen VP Business Development, Bent U. Frandsen
